Needham & Company LLC Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 152.00% from the company’s previous close.

A number of other equities research analysts also recently weighed in on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright lifted their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded down $0.27 during trading on Tuesday, reaching $8.73. The company’s stock had a trading volume of 704,344 shares, compared to its average volume of 822,816. The business’s fifty day moving average price is $9.53 and its 200-day moving average price is $11.58. The firm has a market cap of $462.40 million, a price-to-earnings ratio of -4.15 and a beta of 0.99. Stoke Therapeutics has a one year low of $5.60 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its position in Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares during the last quarter. Geode Capital Management LLC raised its position in Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the last quarter. State Street Corp raised its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the last quarter. RTW Investments LP raised its position in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.